Federated Hermes
ACRS icon

Federated Hermes’s Aclaris Therapeutics ACRS Stock Holding History

Federated Hermes’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-902
Closed -$1.28K – 2115
2025
Q2 		$1.28K Sell
902
-2,040
-69% -$2.76K ﹤0.01% 1984
2025
Q1 		$4.5K Sell
2,942
-1,350
-31% -$2.88K ﹤0.01% 1885
2024
Q4 		$10.6K Sell
4,292
-9,506
-69% -$23.7K ﹤0.01% 1834
2024
Q3 		$15.9K Buy
13,798
+4,259
+45% +$5.22K ﹤0.01% 1767
2024
Q2 		$10.5K Buy
9,539
+1,280
+15% +$1.5K ﹤0.01% 1772
2024
Q1 		$10.2K Buy
8,259
+3,676
+80% +$4.38K ﹤0.01% 1774
2023
Q4 		$4.81K Buy
+4,583
New +$14K ﹤0.01% 1859
2021
Q2 		– Sell
-291
Closed -$7K – 2194
2021
Q1 		$7K Sell
291
-1,043
-78% -$20.4K ﹤0.01% 2033
2020
Q4 		$9K Sell
1,334
-1,044
-44% -$4.4K ﹤0.01% 1992
2020
Q3 		$6K Sell
2,378
-149
-6% -$333 ﹤0.01% 2008
2020
Q2 		$4K Buy
2,527
+2,248
+806% +$3.01K ﹤0.01% 2013
2020
Q1 		$1K Buy
+279
New +$380 ﹤0.01% 2065

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Federated Hermes's ACRS Position: Q3 2025 in Review

Federated Hermes sold out of Aclaris Therapeutics (ACRS) in Q3 2025, closing a stake of 902 shares — an estimated $1.28K sold.

Federated Hermes first reported a position in ACRS in Q1 2020 and held it in 12 quarters. The position peaked at $15.9K in Q3 2024. 103 funds tracked by Wall St. Rank hold ACRS as of Q3 2025.

  • Federated Hermes reported no remaining Aclaris Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Federated Hermes sold 902 Aclaris Therapeutics shares in Q3 2025, an estimated $1.28K.
  • Federated Hermes first reported a position in Aclaris Therapeutics in Q1 2020 and held it in 12 quarters.
  • Federated Hermes's Aclaris Therapeutics position peaked at $15.9K in Q3 2024.
  • 103 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2025.

Based on Federated Hermes's 13F filing for Q3 2025, filed 3 Nov 2025.